AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

NeuroKaire Secures $10M to Transform Precision Medicine in Psychiatry and Neurology

Home
/
update
/
details

Myriad Genetics and Flatiron Health Collaborate to Expand Access to Genetic Testing Through EMR Integration

NextEdge Admin

16 Oct 2024

2 min 8 sec

Flatiron Health,Genetic Testing,EMR Integration

Myriad Genetics, a leader in genetic testing and precision medicine, has partnered with Flatiron Health, a health tech company focused on oncology solutions, to enhance access to genetic testing through electronic medical record (EMR) integration. This collaboration enables providers to order Myriad’s MyRisk® Hereditary Cancer Test and view results seamlessly within Flatiron’s OncoEMR® platform—the first hereditary cancer test integrated into OncoEMR.

Through this partnership, more than 4,200 providers across 800 community-based cancer care centers in Flatiron’s network can order, receive, and review MyRisk test results directly in their existing EMR workflows. This streamlined approach supports personalized care by providing clinicians with quick access to germline testing results at the point of care, minimizing administrative work and improving turnaround times.

“Our collaboration with Flatiron simplifies genetic testing within existing workflows, helping clinicians deliver personalized care,” said George Daneker Jr., MD, President and Chief Clinical Officer of Oncology at Myriad Genetics. “We are excited to explore further genomic testing integrations with OncoEMR to meet even more patient needs.”

Stephen Speicher, MD, Senior Medical Director at Flatiron Health, emphasized the value of the integration in advancing precision medicine: “By embedding MyRisk testing into OncoEMR, we help physicians efficiently access critical genetic information, improving patient outcomes and care delivery.”

The MyRisk integration is now available to all OncoEMR users.